Pfizer Stock Is On A Two-Month Tear — But Is It A Buy?

Pfizer stock pulled back in mid-December, but remains above its key moving averages, on a series of good news for its Covid and respiratory syncytial virus vaccines. X This month, alone, the Food and Drug Administration granted a priority review for Pfizer's (PFE) RSV vaccine in older adults. RSV…#molnupiravir #bntx #comirnaty #ibd #compositeratings #lyme #pfizer #allisongatlin #technicalanalysis #fdamullsits
Source: Reuters: Health - Category: Consumer Health News Source Type: news